Rep. Kevin Hern Unloads Shares of Biogen Inc. (NASDAQ:BIIB)

Key Points

• Rep. Kevin Hern sold $1,001–$15,000 of Biogen shares from his traditional IRA on August 18, alongside sales of several other large-cap holdings between August 18 and 24.
• Biogen shares were up 3.1% at $222.67, near their 52-week high, after the company reported quarterly earnings of $3.60 per share and revenue of $2.74 billion, beating analyst expectations.
• Analyst sentiment remains favorable, with a “Moderate Buy” consensus and an average price target of $227.79. Recent positive developments include China’s approval of an at-home LEQEMBI formulation and encouraging long-term data for the zorevunersen pipeline program.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Biogen Inc. NASDAQ: BIIB. In a filing disclosed on September 01st, the Representative disclosed that they had sold between $1,001 and $15,000 in Biogen stock on August 18th. The trade occurred in the Representative's "KEVIN HERN TRADITIONAL IRA" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Marsh & McLennan Companies NYSE: MRSH on 8/24/2026.
• Sold $15,001 - $50,000 in shares of Medtronic NYSE: MDT on 8/24/2026.
• Sold $50,001 - $100,000 in shares of Home Depot NYSE: HD on 8/24/2026.
• Sold $50,001 - $100,000 in shares of Procter & Gamble NYSE: PG on 8/24/2026.
• Sold $1,001 - $15,000 in shares of Lowe's Companies NYSE: LOW on 8/24/2026.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 8/21/2026.
• Sold $1,001 - $15,000 in shares of Veralto NYSE: VLTO on 8/21/2026.
• Sold $15,001 - $50,000 in shares of Honeywell Aerospace NASDAQ: HONA on 8/19/2026.
• Sold $1,001 - $15,000 in shares of Colgate-Palmolive NYSE: CL on 8/19/2026.
• Sold $1,001 - $15,000 in shares of Anheuser-Busch InBev SA/NV NYSE: BUD on 8/18/2026.

Biogen Stock Up 3.1%

Shares of NASDAQ:BIIB opened at $222.67 on Thursday. The company has a fifty day moving average of $208.99 and a 200-day moving average of $196.25. The company has a market capitalization of $32.90 billion, a PE ratio of 39.41, a price-to-earnings-growth ratio of 2.39 and a beta of 0.17. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. Biogen Inc. has a 52-week low of $135.39 and a 52-week high of $225.59.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.Biogen's revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter last year, the business posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities analysts predict that Biogen Inc. will post 12.39 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on BIIB shares. UBS Group increased their target price on Biogen from $225.00 to $240.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Zacks Research raised Biogen from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 28th. Oppenheimer reiterated an "outperform" rating and issued a $300.00 price objective on shares of Biogen in a report on Wednesday, July 29th. Wolfe Research upgraded shares of Biogen from a "peer perform" rating to an "outperform" rating and set a $300.00 target price on the stock in a research report on Thursday, August 13th. Finally, Wedbush boosted their target price on shares of Biogen from $201.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Biogen has an average rating of "Moderate Buy" and an average price target of $227.79.

Hedge Funds Weigh In On Biogen

Hedge funds have recently made changes to their positions in the stock. Reflection Asset Management acquired a new stake in Biogen during the 4th quarter valued at approximately $25,000. Bell Investment Advisors Inc acquired a new position in shares of Biogen in the 2nd quarter worth approximately $27,000. WFA of San Diego LLC acquired a new position in shares of Biogen in the 2nd quarter worth approximately $32,000. Root Financial Partners LLC boosted its stake in shares of Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 123 shares during the last quarter. Finally, MV Capital Management Inc. bought a new stake in shares of Biogen in the 4th quarter valued at $34,000. 87.93% of the stock is currently owned by institutional investors.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: China approved LEQEMBI SC-AI, Eisai and Biogen’s once-weekly subcutaneous autoinjector for patients with mild cognitive impairment or mild Alzheimer’s disease dementia. The at-home treatment provides an alternative to biweekly hospital infusions, potentially improving patient adherence, reducing clinic visits and lowering healthcare-resource requirements. China represents a substantial long-term market, with an estimated 17 million people affected by early Alzheimer’s disease in 2024. Launch is planned during Eisai’s fiscal 2026. China approval of LEQEMBI SC-AI
• Positive Sentiment: Zorevunersen data supported pipeline optimism. Four-year follow-up in Dravet syndrome showed durable seizure reductions and sustained cognitive and behavioral improvements, with a generally well-tolerated safety profile. Completion of enrollment in the Phase 3 EMPEROR study adds a meaningful late-stage development milestone for Biogen’s partnered pipeline. Zorevunersen clinical data
• Positive Sentiment: Commercial sentiment around LEQEMBI improved after Canada’s drug agency issued a positive recommendation supporting public reimbursement for eligible early-Alzheimer’s patients. Recent analyst target increases also reinforced expectations for LEQEMBI uptake and Biogen’s transition toward newer growth assets. Canada LEQEMBI reimbursement recommendation
• Neutral Sentiment: Biogen completed its acquisition of RayThera to expand into small-molecule immunology therapies. The lead program has only recently entered Phase 1, so the deal offers strategic diversification but carries clinical, execution and financial risks before it can contribute material revenue. Biogen RayThera acquisition

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source